Glenmark Mexico – Eugenio Garcia Verde, General Manager
Eugenio Garcia Verde, general manager at Glenmark Mexico, reveals the company’s ambitious aim to see the brand amongst the top 40 in Mexico and top 20 worldwide by 2020. …
Founded in India in 1977, today Glenmark is a leading player in the discovery of new molecules, with a significant presence in branded generics markets across emerging economies and APIs in regulated and semi-regulated countries. Glenmark employs over 10,400 people in over 80 countries, relies on 14 manufacturing facilities in four countries (India, Argentina, Czech and Brazil) and 6 R&D centres (India, UK and Switzerland). In Mexico the company was constituted back in 2008 with commercial operations starting in 2009.
Contact details
Torre Diamante
Insurgentes Sur 1685 Piso 9 Desp. 903.
Col. Guadalupe Inn, Del. Álvaro Obregón
CP 01020, México DF
MEXICO
Tel: +52 (55) 5663-0554
Website: www. glenmarkpharma.com
Eugenio Garcia Verde, general manager at Glenmark Mexico, reveals the company’s ambitious aim to see the brand amongst the top 40 in Mexico and top 20 worldwide by 2020. …
Javier Amtmann, the new president of AMIIF, the Mexican association of pharmaceutical innovators, reveals AMIIF’s strategic priorities and key areas of focus. As Chairman of the Board of Menarini Mexico,…
Xavier Valdez analyses the dynamics impacting the Mexican pharmaceutical market and explains why IMS Health is transforming itself to strengthen its position as the partner of choice for decision-makers throughout the…
The Mexican pharmaceutical market’s capacity to change dramatically in a short period of time means that both innovators and generics companies must think strategically and “play their cards right” in…
Patricia Ostrosky, general director of the Institute of Biomedical Research in Mexico, details current research subjects and calls for greater collaboration between Mexican universities and the pharmaceutical industry to bring…
Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de…
For Cristóbal Thompson, Executive Director of AMIIF, health is a formidable measure of productivity and competitiveness that Mexico can no longer overlook if it is to sustain robust economic growth. He…
Tackling both obesity and diabetes is a primary objective of the National Academy of Medicine of Mexico and requires a holistic, multidisciplinary approach, according to Dr. Graue Wiechers, president of…
Senator Salvador Brito, President of the Health Commission at the Mexican Senate, talks about increasing access to quality healthcare services among the most vulnerable groups in Mexican society, improving and…
Servier GM Florent Darchez, reveals how he turned around a Mexico affiliate that was losing market share to achieve and impressive sales growth of 30 percent a year. Darchez also…
In part two of a two-part interview (read part one here), Mikel Arriola of the IMSS discusses the strategic roadmap IMSS will follow under his tenure with regards to innovation…
In part one of a two-part interview (read part two here), Mikel Arriola, the recently appointed general director of IMSS (Mexican Social Security Institute), which provides health-related services to more…
Rafael Suarez, general manager of Ferring in Mexico, explains how the Swiss biopharmaceutical company is adapting to the recent dynamics affecting both the Mexican public and private sectors. He outlines…
See our Cookie Privacy Policy Here
